Plexiform neurofibroma - Pipeline Insight, 2025
Description
DelveInsight’s, “Plexiform neurofibroma - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Plexiform neurofibroma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Plexiform neurofibroma: Overview
Plexiform neurofibromas are a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Although these tumors tend to grow slowly, they may grow to an enormous size and can cause serious disfigurement, brain dysfunction or impingement on other organs. They may also cause pain. Until recently, the only known effective treatment for plexiform neurofibromas has been surgery. Approximately 75% of patients who undergo a complete removal of the tumor without causing significant neurologic impairment or dysfunction are cured. Although diagnosis of these lesions is usually possible by examination of the child, the full extent of the lesion is best seen by MRI scan. MRI scans may show these lesions to be much more extensive than previously thought. For those patients with tumors around the spine, the lesions may be extremely extensive.
""Plexiform neurofibroma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Plexiform neurofibroma pipeline landscape is provided which includes the disease overview and Plexiform neurofibroma treatment guidelines. The assessment part of the report embraces, in depth Plexiform neurofibroma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Plexiform neurofibroma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Plexiform neurofibroma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Plexiform neurofibroma Emerging Drugs
Further product details are provided in the report……..
Plexiform neurofibroma: Therapeutic Assessment
This segment of the report provides insights about the different Plexiform neurofibroma drugs segregated based on following parameters that define the scope of the report, such as:
Plexiform neurofibroma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Plexiform neurofibroma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plexiform neurofibroma drugs.
Plexiform neurofibroma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Plexiform neurofibroma: Overview
Plexiform neurofibromas are a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Although these tumors tend to grow slowly, they may grow to an enormous size and can cause serious disfigurement, brain dysfunction or impingement on other organs. They may also cause pain. Until recently, the only known effective treatment for plexiform neurofibromas has been surgery. Approximately 75% of patients who undergo a complete removal of the tumor without causing significant neurologic impairment or dysfunction are cured. Although diagnosis of these lesions is usually possible by examination of the child, the full extent of the lesion is best seen by MRI scan. MRI scans may show these lesions to be much more extensive than previously thought. For those patients with tumors around the spine, the lesions may be extremely extensive.
""Plexiform neurofibroma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Plexiform neurofibroma pipeline landscape is provided which includes the disease overview and Plexiform neurofibroma treatment guidelines. The assessment part of the report embraces, in depth Plexiform neurofibroma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Plexiform neurofibroma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Plexiform neurofibroma R&D. The therapies under development are focused on novel approaches to treat/improve Plexiform neurofibroma.
This segment of the Plexiform neurofibroma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Plexiform neurofibroma Emerging Drugs
- Mirdametinib: SpringWorks Therapeutics
- Binimetinib: Array BioPharma
Further product details are provided in the report……..
Plexiform neurofibroma: Therapeutic Assessment
This segment of the report provides insights about the different Plexiform neurofibroma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Plexiform neurofibroma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Plexiform neurofibroma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Plexiform neurofibroma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plexiform neurofibroma drugs.
Plexiform neurofibroma Report Insights
- Plexiform neurofibroma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Plexiform neurofibroma drugs?
- How many Plexiform neurofibroma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Plexiform neurofibroma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Plexiform neurofibroma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Plexiform neurofibroma and their status?
- What are the key designations that have been granted to the emerging drugs?
- SpringWorks Therapeutics
- Array BioPharma
- Novartis
- Shanghai Fosun Pharmaceutical Development Co, Ltd.
- Ashvattha Therapeutics
- Mirdametinib
- Binimetinib
- Everolimus
- FCN-159
- Nivolumab
- Research programme: hydroxyl dendrimer therapeutics
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Plexiform neurofibroma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Plexiform neurofibroma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Mirdametinib: SpringWorks Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Plexiform neurofibroma Key Companies
- Plexiform neurofibroma Key Products
- Plexiform neurofibroma- Unmet Needs
- Plexiform neurofibroma- Market Drivers and Barriers
- Plexiform neurofibroma- Future Perspectives and Conclusion
- Plexiform neurofibroma Analyst Views
- Plexiform neurofibroma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
